Treating Immune Related Pneumonitis

Abstract: Immunotherapy inhibits the PD-1, PD-L1, CTLA-4 checkpoints, enhancing the function of T-lymphocytes, resulting in the destruction of cancer cells, mainly through the pathway of apoptosis. As with several anticancer regiments, as in the case of immunotherapy, there has been a toxic, inflammatory clinical situation. One of the side effects and in several cases life-threatening patients is pneumonitis, which should be a priority in nursing care. This is why nurses must be well trained and informed so they can properly evaluate the patient and intervene following the international clinical practice guidelines.